RVMD Initiates Phase III Zoldonrasib Trial in PDAC; Pipeline Expansion Adds Cost Without Reducing Binary Risk

What happened

Revolution Medicines has started a Phase III study of zoldonrasib plus chemotherapy in first-line metastatic PDAC with RAS G12D mutations. While this expands the company's pipeline beyond daraxonrasib, it also increases the already high cash burn with no near-term revenue offset. The DeepValue report maintains a POTENTIAL SELL rating, citing the stock's ~$98 price and ~$19B market cap without any approved products or near-term catalysts. The recent M&A premium, which briefly spiked the stock on AbbVie speculation, has proven fragile after AbbVie denied talks. Investors should view this news as incremental pipeline depth that does not de-risk the pivotal 2026 daraxonrasib readout, which remains the primary value driver.

Implication

Holding through the 2026 daraxonrasib readout remains a high-risk binary bet; the new zoldonrasib trial does not justify the current premium. Only consider re-entry after a significant pullback or clear positive pivotal data.

Thesis delta

No material shift: the initiation of a Phase III zoldonrasib trial supports the multi-asset RAS(ON) franchise narrative but does not reduce dependence on daraxonrasib's 2026 pivotal data. The thesis remains a POTENTIAL SELL, as valuation still embeds high expectations for daraxonrasib success and M&A optionality, while cash burn continues to mount.